Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Breast Neoplasms 84Neoplasm Metastasis 8Neoplasms 6Sarcoma 4Squamous Cell Carcinoma of Head and Neck 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Head and Neck Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Wilms Tumor 1Urinary Bladder Neoplasms 1Untreated Operable Early Breast Cancer 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Teratoma 1Somatostatinoma 1Solid Tumors 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Squamous Cell Lung Carcinoma 1Rectal Neoplasms 1

Interventions

palbociclib 1mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × KRAS Mutant Non-Small Cell Lung Cancer × palbociclib × Clear all
NCT02022982 2024-03-19

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
60 enrolled
Other solid neoplasmThoracic

KRAS Mutant Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡